Literature DB >> 32243222

Molecular Risk Stratification in Aggressive B-Cell Lymphomas.

Zachary A K Frosch1, Daniel J Landsburg2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32243222      PMCID： PMC7302956          DOI： 10.1200/JCO.19.03069

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  19 in total

1.  Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

Authors:  Tina Marie Green; Ken H Young; Carlo Visco; Zijun Y Xu-Monette; Attilio Orazi; Ronald S Go; Ole Nielsen; Ole V Gadeberg; Torben Mourits-Andersen; Mikael Frederiksen; Lars Møller Pedersen; Michael Boe Møller
Journal:  J Clin Oncol       Date:  2012-06-04       Impact factor: 44.544

2.  MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.

Authors:  Christiane Copie-Bergman; Peggy Cuillière-Dartigues; Maryse Baia; Josette Briere; Richard Delarue; Danielle Canioni; Gilles Salles; Marie Parrens; Karim Belhadj; Bettina Fabiani; Christian Recher; Tony Petrella; Nicolas Ketterer; Frederic Peyrade; Corinne Haioun; Inga Nagel; Reiner Siebert; Fabrice Jardin; Karen Leroy; Jean-Philippe Jais; Herve Tilly; Thierry Jo Molina; Philippe Gaulard
Journal:  Blood       Date:  2015-09-15       Impact factor: 22.113

3.  P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC/BCL2 expression in diffuse large B-cell lymphoma.

Authors:  Xuan J Wang; Carlos E Bueso-Ramos; Guilin Tang; Sa Wang; Yasuhiro Oki; Parth Desai; Joseph D Khoury; Roberto N Miranda; Zhenya Tang; Nishitha Reddy; Shaoying Li
Journal:  Mod Pathol       Date:  2016-10-14       Impact factor: 7.842

Review 4.  The 2016 revision of the World Health Organization classification of lymphoid neoplasms.

Authors:  Steven H Swerdlow; Elias Campo; Stefano A Pileri; Nancy Lee Harris; Harald Stein; Reiner Siebert; Ranjana Advani; Michele Ghielmini; Gilles A Salles; Andrew D Zelenetz; Elaine S Jaffe
Journal:  Blood       Date:  2016-03-15       Impact factor: 22.113

Review 5.  Double-hit B-cell lymphomas.

Authors:  Sietse M Aukema; Reiner Siebert; Ed Schuuring; Gustaaf W van Imhoff; Hanneke C Kluin-Nelemans; Evert-Jan Boerma; Philip M Kluin
Journal:  Blood       Date:  2010-11-30       Impact factor: 22.113

6.  A Clinician's Approach to Double-Hit Lymphoma: Identification, Evaluation, and Management.

Authors:  Ashley D Staton; Jonathon B Cohen
Journal:  J Oncol Pract       Date:  2016-03       Impact factor: 3.840

Review 7.  How I treat double-hit lymphoma.

Authors:  Jonathan W Friedberg
Journal:  Blood       Date:  2017-06-09       Impact factor: 22.113

8.  Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival.

Authors:  Nathalie A Johnson; Kerry J Savage; Olga Ludkovski; Susana Ben-Neriah; Ryan Woods; Christian Steidl; Martin J S Dyer; Reiner Siebert; John Kuruvilla; Richard Klasa; Joseph M Connors; Randy D Gascoyne; Douglas E Horsman
Journal:  Blood       Date:  2009-07-13       Impact factor: 22.113

9.  Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium.

Authors:  Andreas Rosenwald; Susanne Bens; Ranjana Advani; Sharon Barrans; Christiane Copie-Bergman; Mad-Helenie Elsensohn; Yaso Natkunam; Maria Calaminici; Birgitta Sander; Maryse Baia; Alexandra Smith; Daniel Painter; Luu Pham; Shuchun Zhao; Marita Ziepert; Ekaterina S Jordanova; Thierry J Molina; Marie José Kersten; Eva Kimby; Wolfram Klapper; John Raemaekers; Norbert Schmitz; Fabrice Jardin; Wendy B C Stevens; Eva Hoster; Anton Hagenbeek; John G Gribben; Reiner Siebert; Randy D Gascoyne; David W Scott; Philippe Gaulard; Gilles Salles; Catherine Burton; Daphne de Jong; Laurie H Sehn; Delphine Maucort-Boulch
Journal:  J Clin Oncol       Date:  2019-09-09       Impact factor: 44.544

10.  High-resolution architecture and partner genes of MYC rearrangements in lymphoma with DLBCL morphology.

Authors:  Lauren C Chong; Susana Ben-Neriah; Graham W Slack; Ciara Freeman; Daisuke Ennishi; Anja Mottok; Brett Collinge; Pau Abrisqueta; Pedro Farinha; Merrill Boyle; Barbara Meissner; Robert Kridel; Alina S Gerrie; Diego Villa; Kerry J Savage; Laurie H Sehn; Reiner Siebert; Ryan D Morin; Randy D Gascoyne; Marco A Marra; Joseph M Connors; Andrew J Mungall; Christian Steidl; David W Scott
Journal:  Blood Adv       Date:  2018-10-23
View more
  2 in total

Review 1.  Altered pathways and targeted therapy in double hit lymphoma.

Authors:  Yuxin Zhuang; Jinxin Che; Meijuan Wu; Yu Guo; Yongjin Xu; Xiaowu Dong; Haiyan Yang
Journal:  J Hematol Oncol       Date:  2022-03-18       Impact factor: 17.388

2.  Saudi Lymphoma Group's Clinical Practice Guidelines for Diagnosis, Management and Follow-up of Patients with Various Types of Lymphoma during the Coronavirus Disease 2019 Pandemic.

Authors:  Musa Alzahrani; Mubarak M Al-Mansour; John Apostolidis; Ahmed Barefah; Reyad Dada; Ayman Alhejazi; Yasir Alayed; Ibraheem Motabi; Mansoor Radwi; Hani Al-Hashmi
Journal:  Saudi J Med Med Sci       Date:  2020-08-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.